Jiangsu Simcere Pharmaceutical Co., Ltd.
Jiangsu Simcere Pharmaceutical Co., Ltd.
Explore linked clinical trials.24 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-08-28 | NCT06375044 | |
| A Study of SIM0689 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | cancer, neoplasm | Recruiting | Phase 1 | 2026-08-20 | NCT07660432 | |
| A Phase I Study of SIM0532 in Adult Participants With Advanced Solid Tumors | Histologically or Cytologically Confirmed Advanced Solid Tumors | Active, not recruiting | Phase 1 | 2026-08-11 | NCT07749703 | |
| A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-08-11 | NCT06680921 | |
| Safety and Efficacy of Edaravone Dexborneol Sublingual Tablets for Blood-Brain Barrier Dysfunction in CADASIL | Cerebral Small Vessel Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, brain disorder, brain infarction, brain ischemia, cardiovascular disorder, central nervous system disorder, cerebral arterial disease, cerebral infarction, cerebrovascular disorder, dementia, hereditary disease, intracranial arterial disease, ischemic disease, nervous system disorder, stroke disorder, vascular dementia, vascular disorder | Not yet recruiting | Phase 2 | 2026-07-09 | NCT07692399 | |
| SIM0613 in Participants With Advanced Solid Tumors | Advanced Solid Cancer | Recruiting | Phase 1 | 2026-06-01 | NCT07618260 | |
| A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of SIM0811 Injection in Healthy Chinese Adult Participants | Health, Subjective | Recruiting | Phase 1 | 2026-05-20 | NCT07345364 | |
| the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Enrolling by invitation | Phase 2 | 2026-01-28 | NCT06370416 | |
| First in Human Study of SIM0610 in Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenocarcinoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, head and neck squamous cell carcinoma, hepatocellular carcinoma, intestinal disorder, liver disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, rectal disorder, respiratory system disorder, respiratory tract neoplasm, squamous cell carcinoma | Recruiting | Phase 1 | 2026-01-23 | NCT07348211 | |
| A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2026-01-22 | NCT07361003 | |
| An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult Participants | Healthy Adult Participants | Recruiting | Phase 1 | 2026-01-22 | NCT07357610 | |
| A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions | Neoplasms by Site, Pleural Effusion, Pleural Effusion, Malignant, Thoracic Neoplasms, neoplasm, pleural disorder, pleural neoplasm, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-01-02 | NCT04914598 | |
| Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal disorder, esophageal squamous cell carcinoma, neoplasm, squamous cell carcinoma, squamous cell neoplasm | Recruiting | Phase 2 | 2025-12-05 | NCT07266493 | |
| A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors | Advanced Solid Cancer | Recruiting | Phase 1 | 2025-12-05 | NCT07265921 | |
| A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Not yet recruiting | Phase 2 | 2025-09-23 | NCT07175233 | |
| A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors | Locally Advanced Solid Tumors | Recruiting | Phase 1 | 2025-07-03 | NCT07050459 | |
| A Phase I Study of SIM0388 in Participants With Malignant Ascites. | Malignant Ascites | Recruiting | Phase 1 | 2025-06-06 | NCT07007988 | |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 1 | 2025-01-15 | NCT06186414 | |
| Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 | 2025-01-07 | NCT06686745 | |
| Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 1 | 2024-11-29 | NCT05293964 | |
| Mass Balance Clinical Trial of SIM0270 | Healthy Participants | Active, not recruiting | Phase 1 | 2024-11-27 | NCT06654791 | |
| Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 2 | 2024-11-21 | NCT06698965 | |
| A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Recruiting | Phase 1 | 2022-09-06 | NCT05528055 | |
| Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients | non-Hodgkin lymphoma | Recruiting | Phase 1 / Phase 2 | 2020-12-08 | NCT04440436 |